Proactive Investors: Cardiol Therapeutics enrols first patient in Phase 2 study of CardiolRx for Recurrent Pericarditis

Upcoming Event Cardiol Therapeutics 2023 Annual General Meeting of ShareholdersJun 28, 2023

Past Event FORCE Family Office Webinar – Cardiol Therapeutics: David Elsley, President & CEOApr 11, 2023

Past Event InvestorIntel: David Elsley of Cardiol Therapeutics talks about their global Phase II clinical trials for the treatment of heart diseasesJan 27, 2023